Korean J Intern Med.
2017 Jul;32(4):656-667. 10.3904/kjim.2016.016.
Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II
- Affiliations
-
- 1Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea. myungho@chollian.net
- 2Department of Cardiology, Konyang University Hospital, Daejeon, Korea.
- 3Department of Cardiology, Wonkwang University Hospital, Iksan, Korea.
- 4Department of Cardiology, Korea University Guro Hospital, Seoul, Korea.
- 5Department of Cardiology, Keimyung University Dongsan Medical Center, Daegu, Korea.
- 6Department of Cardiology, Inje University Ilsan Paik Hospital, Goyang, Korea.
- 7Department of Cardiology, Chung-Ang University Hospital, Seoul, Korea.
- 8Department of Cardiology, Pusan National University Hospital, Busan, Korea.
- 9Department of Cardiology, Seoul National University Bundang Hospital, Seongnam, Korea.
- 10Department of Cardiology, Gachon University Gil Medical Center, Incheon, Korea.
- 11Department of Cardiology, Daegu Catholic University Medical Center, Daegu, Korea.
- KMID: 2387711
- DOI: http://doi.org/10.3904/kjim.2016.016
Abstract
- BACKGROUND/AIMS
We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients.
METHODS
Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month.
RESULTS
There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (-42.05 ± 32.73 mg/dL vs. -34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (-20.16 ± 54.49 mg/dL in 4 mg group and -24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (-0.13% ± 1.21% in 4 mg group and -0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively).
CONCLUSIONS
Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
Keyword
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Invasive Treatment of Acute Myocardial Infarction: What is the Optimal Therapy for Acute Myocardial Infarction?
- Primary Coronary Stenting as a Successful Treatment of Acute Myocardial
- Serum Myoglobin in the Early Phase of Acute Myocardial Infarction
- Can time delay be shortened in the treatment of acute myocardial infarction?: Experience from Korea acute myocardial infarction registry
- Effect of Angina Pectoris before Acute Myocardial Infarction on Degree of Residual Stenosis after Successful Coronary Thrombolysis
